

Evidence Table 10. Control of Factors Affecting Asthma: Immunotherapy

Abbreviations used in table:

A. artemisiifolia	Ambrosia artemisiifolia	Der p	Dermatophagoides pteronyssinus
Amb a 1	Ambrosia artemisiifolia	IgE	immunoglobulin E
BPT	bronchial provocation test	IQR	interquartile range
Der f	Dermatophagoides farinae	SIT	specific immunotherapy

* indicates primary outcome

Evidence Table 10. Control of Factors Affecting Asthma: Immunotherapy

Citation (Sponsor)	Study Design	Study Population		
		Study N (Number Evaluable)	Population Characteristics	Asthma Severity at Baseline (if reported)
Johnstone & Dutton. The value of hyposensitization therapy for bronchial asthma in children—a 14-year study. <i>Pediatrics</i> 1968;42(5):793–801.	Prospective, randomized comparative study	210 (131 who had reached 16th birthday)	Age 20% <1 yr, 23% 1–3 yr, 30% 3–6 yr, 21% older than 6 yr Gender 67% male, 33% female Ethnicity Not reported	Perennial bronchial asthma
Olsen et al. A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. <i>Allergy</i> 1997;52(8):853–859.	Randomized, double-blind, placebo-controlled trial (randomization stratified by age, gender, and severity of asthma)	31 (23)	Age 18–64 yr, mean = 34.3 yr Gender Not reported Ethnicity Not reported Weight 52–89 kg/mean = 73.1 kg Height 158–191 cm, mean = 178 cm	Clinical history indicating asthma due to house-dust mites Positive skin prick test with allergen extracts of house-dust mites Significant level of specific IgE antibodies to Der p and Der f in sera Positive bronchial provocation test with Der p and Der f
Gonzalez et al. Immunotherapy with an extract of <i>Olea europaea</i> quantified in mass units. <i>J Investig Allergol Clin Immunol</i> 2002;12(4):263–271.	Randomized, open, controlled parallel groups trial Study conducted in Southern Spain	46 (46)	Age Median 13 in active group and 24 in control group Gender 37% male, 63% female Ethnicity Not reported	20.9% mild asthma, 44.2% moderate asthma, 25.6% severe asthma Clinical history of rhinitis and/or asthma caused by sensitization to <i>Olea europaea</i> with ≥ 2 years of evolution Positive skin-prick test to <i>Olea</i> and specific IgE to that allergen class 2 or higher

Citation (Sponsor)	Study Design	Study Population		
		Study N (Number Evaluable)	Population Characteristics	Asthma Severity at Baseline (if reported)
Pifferi et al. Benefits of immunotherapy with a standardized Dermatophagoides pteronyssinus extract in asthmatic children: a three-year prospective study. Allergy 2002;57(9):785–790.	Randomized, placebo-controlled trial	29 (25)	Age 6–14 yr, mean = 10.6 yr Gender 55% male, 45% female Ethnicity Not reported	At least 5 episodes of doctor-diagnosed asthma in past 12 months Mean = 8.3 exacerbations/year Monosensitization to house-dust mites confirmed by skin-prick test No previous treatment with specific immunotherapy Salbutamol use, mean = 44.8 days/yr; systemic steroid use, mean = 23.4 days/yr FVC mean = 2.5 L FVC % pred. mean = 99.9 FEV ₁ mean = 2.1 L FEV ₁ % pred. mean = 91.9
Maestrelli et al. Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. J Allergy Clin Immunol 2004;113(4):643–649. (Regione Veneto, Giunta Regionale, Ricerca Sanitaria Finalizzata, Venezia; ALK-Abelló, S.P.A., Lainate, Milano, Italy)	Multicenter, randomized, double-blind, placebo-controlled trial (11 centers)	95 (72)	Age Mean = 21.6 yr, 32% <16 yr Gender 65% male, 35% female Ethnicity Not reported	(Characteristics of those who completed the study) 51% mild, 49% moderate asthma Duration of bronchial asthma >1 year Confirmed sensitization to house-dust mite Absence of concomitant sensitization to perennial allergens other than house-dust mite 49% taking inhaled steroids 26% allergy to grass pollen Bedroom-mite allergens: 58% >2 mcg/g Der p1 24% >2 mcg/g Der f1 Morning PEF % pred. mean = 98.4 FEV ₁ % pred. mean = 96.1

Citation (Sponsor)	Study Design	Study Population		
		Study N (Number Evaluable)	Population Characteristics	Asthma Severity at Baseline (if reported)
Mirone et al. Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of <i>Ambrosia artemisiifolia</i> pollen: a double-blind, placebo-controlled study. <i>Clin Exp Allergy</i> 2004;34(9):1408–1414.	Multicenter, randomized, double-blind, placebo-controlled trial	32 (23 Phase I; 22 Phase II)	Age 23–60 yr, mean = 36.8 yr Gender 56% male, 44% female Ethnicity Not reported	Clinical history of rhinoconjunctivitis (68.8%) and/or asthma (40.6%) in late summer Skin test positive to <i>Ambrosia artemisiifolia</i> extract with specific IgE None with severe asthma
Ameal et al. Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of <i>Dermatophagoides pteronyssinus</i> in allergic asthma. <i>Allergy</i> 2005;60(9):1178–1183. (Laboratorios LETI, S.L; the University of Málaga; the Allergy Department of the Hospital of 'Carlos Haya' of Málaga, Spain)	Randomized, double-blind, placebo-controlled trial	63 (45)	Age 14–48 yr, mean = 23 yr Gender 47% male, 53% female Ethnicity Not reported	Mild-to-moderate asthma Rhinoconjunctivitis because of sensitization to <i>D. pteronyssinus</i> Clinical history suggestive of house-dust-mite allergy Positive skin tests using standardized extract and negative to other common aeroallergens Positive specific bronchial provocation test (BPT) Detectable specific immunoglobulin E (IgE) to dust mite
Roberts et al. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. <i>J Allergy Clin Immunol</i> 2006;117(2):263–268. (ALK-Abelló; Special Trustees, St. Mary's Hospital, London)	Randomized, double-blind, placebo-controlled study	39 (35)	Age 3–16 yr, mean = 9.9 yr Gender 71% male, 29% female Ethnicity White/English/Scottish/Welsh, 74% Black African/Caribbean/Other, 9% Indian subcontinent, 15% White other, 3%	Summer asthma: 86% moderate symptoms, 14% severe symptoms Summer rhinoconjunctivitis: 8.6% mild symptoms, 82.9% moderate symptoms, 8.6% severe symptoms Clinical history of grass pollen-induced asthma requiring ≥ 200 mcg inhaled beclomethasone (or equivalent) daily; median 400 mcg Positive skin-prick test response Specific IgE level >0.7 IU/mL Positive conjunctival provocation test result 40% atopic dermatitis, 6% symptoms on exposure to tree pollen, 20% symptoms on exposure to house-dust mite

Citation (Sponsor)	Study Characteristics			Findings			Other
	Treatment	Dose	Duration of Active Treatment; Duration of Postintervention/Off-Treatment Followup	Taper/Decrease Steroids	Lung Function	Exacerbations/Symptoms	
Johnstone & Dutton. The value of hyposensitization therapy for bronchial asthma in children—a 14-year study. Pediatrics 1968;42(5): 793–801.	<p>Purpose/Objective: To compare the reported numbers of asthma attacks, numbers of days wheezing, and several other items of clinical interest</p> <p>Arm 1 Extracts of all inhalable allergens to which children reacted</p> <p>Arm 2 Extracts of all inhalable allergens to which children reacted</p> <p>Arm 3 Mixtures of individual allergens to which children reacted (highest tolerated dose) (n=67 in treated groups combined)</p> <p>Arm 4 Placebo (n=64 reached age 16)</p>	<p>0.10 mL of 1/10,000,000 dilution, increased weekly to 0.50 mL; given every 28 days.</p> <p>0.10 mL of 1/500,000 dilution, increased weekly to 0.50 mL; increased through 3 dilutions to 0.50 of 1/5,000 dilution reached.</p> <p>Same as Arm 2; highest dose tolerated with constitution reaction to injections was maximum dose given.</p> <p>Buffered saline per “injection schedule.”</p>	<p>Maximum of 14 years; some children reached age 16 before 14 years.</p>			<p>66% of the 1/5,000 group and 78% of the highest tolerated dose group were symptom-free in their 16th year.</p>	<p>By age 16, 22.2% of P and 71.6% of treated groups had outgrown their asthma. Loss of asthma was not related to gender, age of onset, or severity of symptoms when first seen. Previous history of hay fever increased the likelihood of asthma persisting into adolescence.</p>

Citation (Sponsor)	Study Characteristics			Findings			Other
	Treatment	Dose	Duration of Active Treatment; Duration of Postintervention/Off-Treatment Followup	Taper/Decrease Steroids	Lung Function	Exacerbations/Symptoms	
Olsen et al. A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy 1997;52(8): 853–859.	Purpose/Objective: To evaluate the safety and efficacy of allergen-specific immunotherapy in patients suffering from bronchial asthma due to house-dust mites			SIT showed decrease ($p < 0.01$) in use of inhaled β_2 -agonists (46%) and inhaled steroids (38%) with no change in P.	FEV ₁ /FVC ratio increased for SIT (86.5 to 87.5) and decreased for P (77.6 to 76.7); difference between groups after treatment but not before ($p < 0.05$). Bronchial sensitivity decreased to Der p and Der f ($p = 0.022$ and 0.039 , respectively) in SIT with no change in P.	Symptom scores decreased for SIT ($p < 0.001$) with no change for P. Among SIT, 82% classified treatment effect as good or very good vs. in P where all patients classified effect as none or slight ($p = 0.0022$).	No one developed systemic side-effects during uposing or maintenance dosing. No change in skin-prick tests for either group. Total and specific IgE to Der p and Der f show only minor fluctuations with no differences within or between groups.
	Arm 1 Specific immunotherapy with extracts of Der p or Der f (SIT) ($n = 21$; $n = 17$ completers) NOTE: Results are not presented for the 2 extract groups separately.	Single-dose uposing with weekly injections of 100, 1,000, 10,000, and 1,000,000 SQ-U/mL. Maintenance dose of 100,000 SQ-U/mL (~7 mcg Der p1 or ~10 mcg Der f1) reached after 15 weeks.	1 year after 4-week run-in period.				
	Arm 2 Placebo (P) ($n = 10$; 6 completers)	Injections of histamine dihydrochloride in aluminum hydroxide solution; uposing performed with weekly injections on same schedule as for Arm 1.					

Citation (Sponsor)	Study Characteristics			Findings			Other
	Treatment	Dose	Duration of Active Treatment; Duration of Postintervention/Off-Treatment Followup	Taper/ Decrease Steroids	Lung Function	Exacerbations/Symptoms	
Gonzalez et al. Immunotherapy with an extract of <i>Olea europaea</i> quantified in mass units. <i>J Investig Allergol Clin Immunol</i> 2002;12(4): 263–271.	<p>Purpose/Objective: To evaluate the tolerance, safety, and efficacy of specific immunotherapy in monosensitized patients to olive</p> <p>Arm 1 Active treatment: preseasonal immunotherapy from September to April (A) (n=23)</p> <p>Arm 2 Control group (C) (n=23)</p>	<p>Hypersensitizing dose of <i>Olea europaea</i> extract preseasonally to maintenance dose 3.8 times higher than conventional treatment (75 BU corresponding to 45 mcg Ole e 1).</p> <p>Symptomatic treatment only.</p>	<p>(8 months preseason) administered twice with 2-week interval and then every 21 days until start of pollen season.</p>	<p>(within-group comparisons) Decrease in A in use of beta₂-agonists (p<0.01) and antihistamines (p<0.05), but not in C (p>0.10).</p>		<p>(within-group comparisons) Decrease in nasal symptoms in A (p<0.05) but not C (p=0.84). Decrease in pulmonary symptoms in A (p<0.03) but not in C (p>0.14). Comparison between groups in severity of disease favored A (p<0.001). No difference in conjunctival sensitivity for A or C, but higher tolerance in A when maintenance dose reached (p<0.05) that was not kept at end of study. Cutaneous sensitivity of C vs. A was 13.4 times higher after second 14-day dose after reaching maintenance and 4.4 times higher after pollen season (p<0.01).</p>	<p>Differences in evolution (p<0.05) for IgE and IgG₁ and for IgG₄ (p<0.001) for A. 15 AE in A in 7 patients during build-up phase with treatment required in 8 cases. Systemic reactions on 4 occasions in 2 patients, 3 mild and 1 moderate.</p>
Pifferi et al. Benefits of immunotherapy with a standardized <i>Dermatophagoides pteronyssinus</i> extract in asthmatic children: a three-year prospective study. <i>Allergy</i> 2002;57(9): 785–790.	<p>Purpose/Objective: To verify the benefits of specific immunotherapy in children with asthma during a 3-year period</p> <p>Arm 1 Purified standardized allergenic extract of D pt (SIT) (n=15; n=15 completers)</p> <p>Arm 2 Control group (n=14; n=10 completers)</p>	<p>Dosing schedule in accord with EEACI. Dose increased from 1 U, concentration 10 U/mL (volume 0.1) each week to maximum tolerated dose. Maintenance dose 800 U, concentration 1,000 U/mL every 4–6 weeks.</p>	<p>3 years; 1-year run-in period</p>	<p>Reduced salbutamol and systemic steroids intake in SIT vs. controls (p<0.01).</p>	<p>*Final comparison between SIT and controls was not significant for FVC, FEV₁, and FEF_{25–75}. Likelihood of nonimprovement of bronchial reactivity of SIT was one third that of controls (RR 0.3, 95% CI 0.11 to 0.87).</p>	<p>Number of exacerbations decreased among SIT vs. controls after 1st year (p<0.01) and remained at end of 3-year period (p<0.01). Occurrence of new sensitizations was lower in SIT vs. controls (0% vs. 33%; p=0.01).</p>	<p>All subjects reached suggested dose for maintenance phase. No major local or systemic side-effects were reported during treatment period.</p>

Citation (Sponsor)	Study Characteristics			Findings			Other
	Treatment	Dose	Duration of Active Treatment; Duration of Postintervention/Off-Treatment Followup	Taper/Decrease Steroids	Lung Function	Exacerbations/Symptoms	
<p>Maestrelli et al. Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. J Allergy Clin Immunol 2004; 113(4):643–649. (Regione Veneto, Giunta Regionale, Ricerca Sanitaria Finalizzata, Venezia; ALK-Abelló, S.P.A., Lainate, Milano, Italy)</p>	<p>Purpose/Objective: To investigate whether specific immunotherapy is associated with clinical improvement and a significant reduction in antiasthma medication use</p>			<p>No change in average use of inhaled steroids and bronchodilators in the 2 groups.</p>	<p>*Morning and evening PEF improved in SIT (p<0.001) but did not change in P. Average increase in SIT group between 1.6% and 4.7% in morning PEF and between 2.5% and 5.5% for evening PEF during autumn months of last year of study.</p> <p>No difference in FEV₁ or in PD₂₀ FEV₁ between the groups at any visit.</p>	<p>SIT was associated with decrease in skin sensitivity to house-dust-mite extract (p<0.05), whereas there was a trend toward increasing skin reaction to the allergen in P.</p> <p>Median asthma symptom scores in both groups showed nonsignificant decrease during study.</p>	<p>88% of SIT and 94% of P received target maintenance dose.</p>
	<p>Arm 1 Specific immunotherapy (SIT) (n=49; n=41 completers)</p>	<p>Subcutaneous injection of 0.1 mL of a 0.1 BU/mL concentration increased weekly to target maintenance dose of 7 BU in adults and 6 BU in children; maintenance therapy consisted of 6 mcg/mL Der 1 + Der 2 given every 3 weeks.</p>	<p>3 years after observation and stabilization for 1 year.</p> <p>Salbutamol (MDI 100 mcg/actuation) used as bronchodilator; beclomethasone dipropionate (MDI 250 mcg/actuation) used as regular anti-inflammatory agent.</p>				
	<p>Arm 2 Placebo (P) (n=46; n=31 completers)</p>	<p>Aluminum hydroxide solution; histamine (10 mg/mL) added to half of the placebo vials during 1st and 2nd years of treatment.</p>					

Citation (Sponsor)	Study Characteristics			Findings			Other
	Treatment	Dose	Duration of Active Treatment; Duration of Postintervention/Off-Treatment Followup	Taper/Decrease Steroids	Lung Function	Exacerbations/Symptoms	
Mirone et al. Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of <i>Ambrosia artemisiifolia</i> pollen: a double-blind, placebo-controlled study. Clin Exp Allergy 2004;34(9): 1408–1414.	Purpose/Objective: To evaluate the safety and efficacy of specific injective immunotherapy to <i>Ambrosia</i> in European patients					Scores for symptoms (p=0.02) and drugs (p=0.0068) decreased in A after first year with no change for P. Days with asthmatic symptoms (p=0.003), rhinitis symptoms (p=0.05), and intake of drugs (p=0.0058) decreased in A after first year with no change for P. Number of days with rhinitis and with asthma lower in A vs. P (p=0.048 and =<0.0001) after 1 year.	Decrease in skin reactivity for A after 1 year (12.2-fold, p=0.0001) and after 2 years (12.4-fold, p<0.0001) with no difference between 1st and 2nd year of therapy (p=0.47). No change in P after 1st year and decrease (4.8-fold, p=0.0022) after 12 months of active treatment.
	Arm 1 Amb a 1 (A) (n=16; n=11 completed Phase I and Phase II)	Extract of <i>A. artemisiifolia</i> pollen absorbed onto aluminum hydroxide and suspended in phenolated (0.4% w/v) saline solution. Weekly dose increased from 0.09 to 9 mcg/mL Amb a 1.	12 months (3 build-up phases of active treatment followed by maintenance phase); months 12–24, A continued maintenance and P began active therapy.				
	Arm 2 Placebo (P) (n=16; n=12 and n=11 completed Phase I and Phase II)		Oral antihistamine, antihistamine eye drops, antihistamine nasal spray, beta ₂ -agonist, and oral cortisone allowed as rescue drugs.				

Citation (Sponsor)	Study Characteristics			Findings			Other
	Treatment	Dose	Duration of Active Treatment; Duration of Postintervention/Off-Treatment Followup	Taper/Decrease Steroids	Lung Function	Exacerbations/Symptoms	
<p>Ameal et al. Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma. Allergy 2005;60(9): 1178–1183.</p> <p>(Laboratorios LETI, S.L; the University of Málaga; the Allergy Department of the Hospital of 'Carlos Haya' of Málaga, Spain)</p>	<p>Purpose/Objective: To evaluate the clinical efficacy and safety of a depigmented, polymerized vaccine-containing <i>D. pteronyssinus</i></p> <p>Arm 1 Modified allergen extract of <i>D. pteronyssinus</i> (E) (n=32; n=29 completers)</p> <p>Arm 2 Placebo (n=31; n=26 completers)</p>	<p>Both groups received pharmacological treatment, if needed, consisting of oral ebastine, salbutamol, and budesonide.</p>	<p>12 months</p>	<p>E had 56% decrease in medication scores vs. 11.4% decrease in P. After 12 months E had a 68% decrease of medication over P.</p>	<p>*Change in PD₂₀FEV₁ at 12 months was greater for E (median 4.27 HEP, IQR 1.74 to 8.45) vs. P (-0.05 HEP, IQR -1.17 to 5.19) (p=0.0004).</p> <p>At 12 months E needed a median of 4.5 times more extract to achieve the value of 10 HEP whereas P did not change from baseline.</p>	<p>E showed decrease in symptom scores from baseline (p=0.0001) vs. no change in P (p=0.73). At 12 months E had a 78% decrease of symptoms over P.</p> <p>At 12 months E showed improved asthma quality of life scores vs. P (p=0.0025).</p>	<p>Two local reactions with diameter between 5 and 10 cm in E and 3 reactions in P.</p>

Citation (Sponsor)	Study Characteristics			Findings			Other
	Treatment	Dose	Duration of Active Treatment; Duration of Postintervention/Off-Treatment Followup	Taper/Decrease Steroids	Lung Function	Exacerbations/Symptoms	
Roberts et al. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. <i>J Allergy Clin Immunol</i> 2006;117(2): 263–268. (ALK-Abelló; Special Trustees, St. Mary's Hospital, London)	<p>Purpose/Objective: To examine the clinical efficacy and safety of specific immunotherapy in children with seasonal allergic asthma and to measure changes in specific allergen reactivity and airway inflammation</p> <p>Arm 1 Specific immunotherapy (SIT) (n=18)</p> <p>Arm 2 Placebo (P) (n=17)</p>	<p>Alutard SQ <i>P pratense</i> corresponding to 20 mcg of major allergen (Phl p 5) with placebo containing histamine to maintain binding.</p> <p>Placebo identical in color and viscosity.</p>	<p>Two pollen seasons.</p> <p>All subjects allowed to use rescue medications for symptoms of hay fever and asthma during grass pollen season; treated in a step-up/step-down manner according to clinical symptoms.</p>	<p>No difference in reduction in total corticosteroid score (p=0.16) or use of inhaled bronchodilators (p=0.38) between SIT and P.</p>	<p>No difference in highest standardized exhaled nitric oxide (FE_{NO}) in SIT (median 1.77, IQR 1.56 to 2.13) and P (median 1.99, IQR 1.44 to 2.50).</p>	<p>*Reduction in asthma symptom-medication score in SIT vs. P (median 0.5, IQR 0.1 to 0.9 for SIT vs. median 1.0, IQR 0.4 to 2.0 for P; p=0.04).</p> <p>After 1st and 2nd pollen seasons, difference in cutaneous (p=0.003 and p<0.001, respectively) and conjunctival (p=0.002 and p=0.03, respectively) allergen reactivity favored SIT.</p>	<p>72% of SIT and 41% of P reported treatment-related AE.</p>